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Abstract
Background: There is growing evidence that both local and systemic inflammatory responses play an important role 
in the progression of a variety of solid tumors. Colorectal cancer results from the cumulative effect of sequential 
genetic alterations, leading to the expression of tumor associated antigens possibly inducing a cellular anti-tumor 
immune response. It is well recognized that cytotoxic lymphocytes constitute one of the most important effector 
mechanisms of anti-tumor-immunity. However, their potential prognostic influence in colorectal cancer remains 
controversial. Aim of the study was to examine infiltration of CD3+ and CD8+ lymphocytes in colorectal cancer and their 
prognostic potential.
Two-hundred-fifteen colorectal cancer cases, previously analyzed for microsatellite instability (MSI), were selected for
immunohistochemical detection of CD3+, CD8+ infiltration and the expression of granzyme B. Prognostic relevance
was assessed by survival analysis.
Results: Strong correlations were found between the infiltration of lymphocytes and several clinicopathological 
variables. Survival analysis revealed that intra-epithelial infiltration of CD3+ and CD8+ T lymphocytes and stromal 
infiltration of CD3+ lymphocytes had a major impact on the patients' overall survival in the univariate analysis, however 
independent of their association with MSI-status. In addition, it was also demonstrated that there was an important 
disease specific survival advantage for patients with microsatellite stable (MSS) tumors containing intraepithelial CD8+ 
tumor infiltrating lymphocytes. When samples were analyzed for colon cancer and rectal cancer separately, the results 
of the overall population were confirmed in colon cancer only. When entered into a multiple Cox regression analysis 
adjusting for other possible important confounding factors, the strong impact of lymphocyte infiltration on overall 
survival was not maintained. Only early stage and young age (borderline significant for overall population only) were 
associated with a better overall survival (early disease with disease-free survival also).
Conclusions: In conclusion our results suggest a role for infiltrating CD3+ and CD8+ T lymphocytes in colorectal cancer 
whereby tumor infiltration could reflect a general principle of antitumor immunity, irrespective of the MSI-status.
Background
Colorectal cancer belongs to the most common malig-
nancies in the Western World [1]. The treatment of
choice remains surgical resection. For patients who
undergo successful surgery for colorectal cancer, adjuvant
chemotherapy and/or radiotherapy is recommended in
cases of high risk stage II and III disease [2,3]. Although
the introduction of new chemotherapeutic agents
improved the prognosis of colorectal cancer over the past
decades, the outlook for most patients still remains rela-
tive poor [1,3]. Therefore, new treatment options, besides
the standard therapies, seem warranted to further
improve survival of patients with colorectal cancer [4],
especially for stage II disease [5,6]. New approaches focus
on immunotherapeutic strategies as there is growing evi-
dence in recent years supporting the existence of cancer
immunosurveillance [4].
It has been recognized that disease progression in can-
cer patients is not solely determined by the characteris-
tics of the tumor but also by the host response. Indeed,
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there is growing evidence that both local and systemic
inflammatory responses play an important role in the
progression of a variety of solid tumors [7-10]. In addi-
tion, the interrelationship between both inflammatory
responses might have an influence on the outcome of the
disease [7-10]. Colorectal carcinogenesis is a multistep
process, during which (epi)genetic alterations determine
the transition from a normal to a malignant cell. Acquisi-
tion of these alterations requires, among others, destabili-
zation of the genome. Several forms of genetic instability
(microsatellite instability (MSI), chromosomal instability
and epigenetic instability) are believed to be involved in
the development of colorectal cancer. MSI can lead to the
production of abnormal proteins and derived peptides
that, by acting as neo-antigens [11], could induce an
adaptive immune response effective in limiting tumor
growth and/or spread [11-16]. Nevertheless, the antitu-
mor immune response is complex, involving the interac-
tion of several cell types and cell products of the adaptive
as well as the innate immune system [7,17]. On the other
hand, colorectal tumors are also capable of escaping
immune surveillance using several strategies [18].
It is well recognized that cytotoxic T lymphocytes
(CD8+ T cells) constitute one of the most important effec-
tor mechanisms of anti-tumor immunity [17]. In order
for CD8+ T cells to recognize antigens, these need to be
exposed on the tumor cells in association with the human
leukocyte antigen (HLA) class I proteins. Upon encoun-
ter of a tumor cell antigen/HLA I complex for which their
T cell receptor is specific, cytotoxic T lymphocytes clon-
ally expand and subsequently differentiate. Part of the dif-
ferentiation process into killer cells includes the
formation of a large number of modified lysosomes
loaded with perforin and several types of granzymes
[19,20]. These activated cytotoxic T lymphocytes can
mediate specific destruction of tumor cells by the release
of these lytic components in case of direct cell-cell inter-
action. Perforin and enzymatic proteases (such as gran-
zyme B) are released and cause cell death by disruption of
the cell membrane and activation of the apoptotic path-
way respectively [17,21]. In addition, other factors of the
adaptive immune system play a role in the cancer immu-
nosurveillance. CD4+ T cells, which only respond to anti-
gens presented by the HLA class II proteins expressed by
antigen presenting cells (like dendritic cells), are impor-
tant for antitumor immunity. Depending on the cytokine
profile induced, CD4+ T cells are subdivided in T helper-1
cells or T helper-2 cells. Importantly, T helper-1 cells are
essential for the proliferation of cytotoxic T lymphocytes
as these lymphocytes require T helper-1 effector cell pro-
duced interleukin-2 for their proliferation. Although it
has been shown that CD4+ T cells may be sufficient by
themselves to eliminate tumor cells, it is more often the
case that both CD4+ and CD8+ T cells are required for
effective tumor cell elimination because most tumor cells
only express HLA class I molecules. However, the induc-
tion of cytotoxic T lymphocytes responses takes time,
leaving time for the tumor cells to escape the immune
system. Therefore, natural killer cells from the innate
immune system may also play an important role since
these cells can lyse natural killer-sensitive tumor targets
prior to antigen sensitization or clonal expansion. Given
that natural killer cells are not HLA restricted, these cells
bear the capacity to eliminate tumor cells that do not
express HLA. In contrast, HLA complexes are recognized
by inhibitory receptors on natural killer cells resulting in
their inactivation. In addition, natural killer cells express
several ligands of the tumor necrosis factor family and
can induce apoptosis of malignant cell targets which are
phagocytosed by dendritic cells and macrophages and
processed for subsequent presentation to T cells. Fur-
thermore, natural killer cells constitutively express the
interleukin-2 receptor and are able to respond to inter-
leukin-2 stimulation that results in augmented cytotoxic
activity [19].
The potential influence of immune-cell infiltrates in
various neoplasms, including colorectal cancer, on the
prognosis of patients is investigated in several studies but
remains inconclusive [4,22,23]. Pronounced lymphocyte
infiltration in colorectal cancer has been described and is
more marked in MSI-positive tumors [15,16,24-27].
Additionally, these tumors predominantly have a proxi-
mal location and are reported to run a better clinical
course (as reviewed in [28,29]). Some groups found that
stage III colorectal tumors with a high content of intratu-
moral lymphocytes had a more favorable clinical out-
come [30,31]. In contrast, in a randomized trial it was
demonstrated that active specific immunotherapy, using
autologous tumor cells and Bacillus Calmette-Guérin,
had a significant clinical benefit in the adjuvant treatment
of stage II colon cancer only [32,33].
Since several studies [13,30,34] showed the presence of
a cytotoxic antitumor immune response in subsets of col-
orectal cancer, the aim of this study was to examine infil-
tration of CD3+  and CD8+  lymphocytes in colorectal
cancer according to the classification of Naito et al. [24].
Correlation with overall and disease-free survival was
calculated in order to determine the potential prognostic
role of cytotoxic T lymphocytes.
Results
Patient characteristics
Of the 215 colorectal cancer patients from whom tumor
tissue could be obtained, most (but not all) clinical data
could be retrieved. Most tumors were located in the distal
part of the large bowel (63.3%) and most patients had a
stage II or III disease. Further details on these patients are
summarized in Table 1.Deschoolmeester et al. BMC Immunology 2010, 11:19
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Immunohistochemistry
To enhance the power of the study the prognostic rele-
vance of lymphocyte infiltration was assessed based on
the comparison of two levels of infiltration: nil and mild
infiltration on the one hand and moderate and severe
infiltration on the other hand.
Semi-quantitative scoring of inflammatory infiltration
of the three different tumor regions is shown in Table 2
and Figure 1. It is shown that infiltration of CD3+ T cells
is most abundant in the invasive margin while infiltration
of CD8+ cytotoxic T lymphocytes is strongest in the inva-
sive margin and the stroma which means that in this
study population, most T lymphocytes were found in the
invasive margin but the cytotoxic T lymphocytes were
also abundant in the stroma close to the tumor cells. The
expression of granzyme B is much sparser. Approximately
50% of CD8+ T cells express their associated cytotoxic
molecule granzyme B moderately/severely (see also
CD8*GRB in Table 2 and Figure 2).
Strong associations were found between all infiltrating
lymphocytes in the different tumor regions, except for
CD3+ T cells and granzyme B expression in the invasive
margin and the stroma. In addition, several strong corre-
lations were found between the infiltration of lympho-
cytes and clinicopathological variables, such as poorly
differentiated tumors (CD8+ in stroma and cancer cells,
CD3+ and granzyme B in invasive margin), distal location
(CD3+ in cancer cells and granzyme B in invasive mar-
gin), early stage (CD8+ in cancer cells, CD3+ in invasive
margin and cancer cells and granzyme B in cancer cells)
Table 1: Patient characteristics
Patient 
characteristics
Colon Rectum Overall population
Total no. of patients 141 64 215
Median age (years) 70 +/- 12 64 +/- 13 68 +/- 13
Sex
male 62 (44.0%) 40 (62.5%) 107 (49.8%)
Female 79 (56.0%) 24 (37.5%) 106 (49.3%)
Location
proximal 77 (35.8%)
distal 136 (63.3%)
Grade of 
differentiation
poor 17 (12.1%) 2 (3.1%) 19 (8.8%)
moderate 39 (27.7%) 19 (29.7%) 63 (29.3%)
well 83 (58.9%) 39 (60.9%) 126 (58.6%)
Stage
I 15 (10.6%) 15 (23.4%) 30 (14.0%)
II 53 (37.6%) 19 (29.7%) 74 (34.4%)
III 59 (41.8%) 18 (28.1%) 80 (37.2%)
IV 13 (9.2%) 10 (15.6%) 26 (12.1%)
Therapy
Neo-adjuvant Yes 1 (0.7%) 16 (25.0%) 19 (8.8%)
No 128 (90.8%) 44 (68.8%) 178 (82.8%)
Adjuvant Yes 47(61.0%) 30 (45.9%) 81 (37.7%)
No 86 (33.3%) 29 (45.3%) 119 (55.3%)
MSI status
MSI 24 (17.0%) 2 (3.1%) 27 (12.6%)
MSS 117 (83.0%) 62 (96.6%) 188 (87.4%)
Clinical characteristics of patients analyzed for the overall population and for patients with colon cancer and rectal cancer separately (in 10 
patients the actual location of the tumor was not specified; not all clinical characteristics were available for each patient) (MSI: microsatellite 
instability, MSS: microsatellite stability).Deschoolmeester et al. BMC Immunology 2010, 11:19
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and the absence of treatment (CD8+ in all areas CD3+
and granzyme B in invasive margin and stroma).
Correlation of MSI and lymphocyte infiltration
As previously mentioned, all samples had been typed for
MSI using the mononucleotide multiplex system [35].
Twenty-seven out of 215 colorectal samples (12.6%)
showed a high level of MSI (MSI-H) and 188 out of 215
showed microsatellite stability (MSS).
In this study population, sporadic MSI-H tumors were
associated with proximal location (p < 0.001), poor differ-
entiation (p < 0.001), female gender (p = 0.018) and there
was a trend towards early stage (p = 0.077). A higher infil-
tration of CD8+ and CD3+ lymphocytes was noted in all
examined areas of MSI-H tumors compared to MSS
tumors. Granzyme B expression was considerably higher
within the cancer cell nests of MSI-H tumors. In addition,
logistic regression showed that MSI (HR: 5.505, p < 0.001)
and stage (HR: 0.582, p = 0.006) were the major predic-
tors of the presence of activated intraepithelial CD8+ T
lymphocytes whereas grading, age, location and gender
did not show a major impact.
Correlations with survival
Follow up for overall survival was available for 209 col-
orectal cancer patients. At the end of the observation
period, 100 patients (47.8%) were deceased and all deaths
were cancer related. Follow up for disease-free survival
was available for 193 colorectal cancer patients and 57
patients (29.5%) experienced a recurrence of the tumor.
The median follow up for overall and disease-free sur-
vival was 5.2 and 4.9 years respectively.
In univariate survival analysis, patients with MSI-H
tumors showed a slightly longer overall survival than
patients with MSS tumors, however, significance was not
reached (HR: 0.55, 95%CI: 0.26-1.131). As expected,
tumor stage (HR: 2.20, 95%CI: 1.72-2.83) and age (HR:
2.29, 95%CI: 1.51-3.46) had the most impact on overall
survival while only early stage (HR: 2.32, 95%CI: 1.60-
3.37) was correlated with a better disease-free survival.
Furthermore, univariate analysis also showed that female
gender (HR: 1.51, 95%CI: 1.02-2.26), high differentiation
grade (HR: 0.83, 95%CI: 0.70-0.99) and distal location
(HR: 0.65, 95%CI: 0.44-0.98) had an important influence
on longer overall survival. In addition, infiltration of
CD3+ lymphocytes in stroma and in cancer cell nests and
infiltration of CD8+ T lymphocytes in cancer cell nests
had an important impact on overall survival. Further-
more, MSS colorectal cancers with intra-tumoral infiltra-
tion of CD8+ T lymphocytes had a better overall survival
compared to MSI-positive colorectal tumors (figure 3).
M u l t i p l e  C o x  r e g r e s s i o n  a n a l y s i s  w a s  u s e d  t o  v e r i f y
whether the investigated variables concerning T cells are
valid when taking into consideration potential confound-
ing cofactors (Table 3). The positive impact of tumor
infiltrating lymphocytes on overall survival was lost and
only early stage (p < 0.001) and young age (p = 0.04) were
independently associated with a better overall survival.
For disease-free survival, early stage (p < 0.001) was the
only independent factor associated with a better outcome
(table 3).
When samples were analyzed for colon cancer and rec-
tal cancer separately using univariate analysis, infiltration
of CD3+ lymphocytes in stroma and in cancer cell nests
and infiltration of CD8+ T lymphocytes in cancer cell
nests had a major impact on overall survival in colon can-
cer but not in rectal cancer (see further below). In addi-
tion, MSS colon cancers with intra-tumoral infiltration of
CD8+ T lymphocytes had a considerably better overall
survival compared to MSI-positive colon cancers (figure
4). Again, in the multiple Cox regression analysis infiltra-
tion of lymphocytes was not retained as an independent
prognostic factor. The most important confounding fac-
Table 2: Semiquantitative scoring of inflammatory infiltration in colorectal cancer.
infiltration IM ST CC
CD3 0 30.0% 61.7% 70.2%
1 70.0% 38.3% 29.8%
CD8 0 32.9% 38.8% 64.1%
1 67.1% 61.2% 35.9%
GRB 0 63.4% 68.9% 84.7%
1 36.6% 31.3% 15.3%
CD8*GRB 0 51.4% 52.9% 59.0%
1 48.6% 47.1% 41.0%
Semiquantitative scoring of inflammatory infiltration of the three different tumor regions, based on two levels of infiltration. (%: percentage 
of samples with particular scoring, 0: null-mild infiltration, 1: moderate-severe infiltration, IM: invasive margin, ST: stroma, CC: cancer cell 
nests, GRB: granzyme B, CD8*GRB: CD8 T cells expressing GRB).Deschoolmeester et al. BMC Immunology 2010, 11:19
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tor was early stage which was strongly associated with a
better overall and disease-free survival. In contrast, as
mentioned, infiltration of lymphocytes in rectal cancer
had no influence on survival in the univariate analysis.
The administration of pre-operative radiotherapy in rec-
tal cancer might destroy the immune cells present in the
tumor prior to surgical resection. However, when rectal
cancer patients who received pre-operative radiotherapy
were removed from the analysis, the associations
between the infiltration of CD3+ lymphocytes in stroma
and in cancer cell nests and infiltration of CD8+ T lym-
phocytes in cancer cell nests and overall survival were
only slightly stronger in the overall population. Once
more these associations could not be confirmed in the
Cox regression analysis. In addition, infiltration of lym-
phocytes in rectal cancer without pre-operative radio-
therapy still had no influence on survival.
Discussion and Conclusions
Solid tumors are not just composed of malignant cells,
but are complex microcosms of many cell types, includ-
ing a wide range of hematopoietic cells [36]. Anti-tumor
immune responses may be one of the most important
weapons in the arsenal against cancer [37]. Galon et al.
[38,39] suggested that once human colorectal tumors
become clinically detectable, the adaptive immune
response plays a role in preventing tumor recurrence and
metastasis. Intratumoral T cells could modify tumor
stroma or tumor cells in ways that attenuate the meta-
static potential of tumor cells [40,41]. However, it is still
unclear if the presence of tumor infiltrating lymphocytes
represents the result of an inflammatory response that
facilitates either tumor progression or a protective host
response against cancer [4].
The present study confirms that tumor infiltrating lym-
phocytes are present in colorectal cancer and, as
Figure 1 Immunohistochemical staining of lymphocyte infiltration in colorectal cancer. Examples of lymphocyte infiltration in colorectal tu-
mors. A and C: CD8+ T cells infiltrating the invasive margin (A), the stroma (A and C) and in the cancer cell nests (C). B and D: CD3+ cells infiltrating the 
invasive margin (B), the stroma (B and D) and in the cancer cell nests (D).Deschoolmeester et al. BMC Immunology 2010, 11:19
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expected, a strong correlation was found between CD3+
and CD8+ T cells. Additionally, a strong association was
also seen between the presence of CD8+ T lymphocytes
and the expression of their associated cytotoxic molecule
granzyme B in all examined areas of the tumor. Gran-
zyme B expression was much sparser which can be
explained by the fact that only those CD8+ T lymphocytes
which are cytolytic (about 50% in this study) will express
their associated cytotoxic molecule granzyme B. When
exposed to dysfunctional cells, cytotoxic T lymphocytes
will release granzyme B and will eventually induce apop-
tosis of the proximal tumor cells bearing the appropriate
antigen determinants [7,17]. This might hold promise in
the field of immunotherapy [16,42]. Unfortunately, at this
time we were unable to investigate T cell surface activa-
tion markers or the apoptosis status of the infiltrated
tumor cells in order to confirm the lytic function of these
infiltrating T cells.
As found in several other studies [7,39,43-48], the pres-
ence of a pronounced lymphocytic infiltration within the
tumor is associated with improved survival in the current
study. Specifically, CD3+ and CD8+ T lymphocytes within
cancer cell nests of colorectal cancer and of CD3+ in the
colorectal cancer stroma had a major impact on the
patients' overall survival by univariate analysis in the
overall population. When colon and rectal tumors were
investigated separately, the results of the overall popula-
tion were confirmed in the group of colon cancer patients
but not in the group of the rectal cancer patients, even
when the rectal cancer patients receiving pre-operative
radiotherapy were excluded from the analysis.
The improved survival associated with infiltration of
lymphocytes may be the result of an effective suppression
of micrometastases in distant organs or near the primary
site. In other words, the number of CD8+ T cells within
the primary tumor might be a good indicator of the pres-
ence of a systemic immunosurveillance mechanism
[40,41]. In addition, tumor cells can secrete substances in
the stroma, which might be recognized by the immune
system to destroy the tumor.
In accordance to Pages et al. [47], Ropponen et al [44]
and Koch et al [4], but in contrast to Ling et al. [49], stage
was a major determinant of infiltration of activated cyto-
toxic intraepithelial lymphocytes (as shown by multivari-
ate analysis) with a higher infiltration in earlier stages
(HR: 0.582, p = 0.006). This might indicate that immune
reactions may be more prominent in early stages of dis-
ease and might have a stage specific influence on survival
[31,50], possibly irrespective of the MSI-status. There
might be a protective local immune response in these
earlier tumor stages, preventing further tumor growth
and spread. However, this hypothesis has to be substanti-
ated by further analysis of activation status of tumor infil-
trating lymphocytes in patients with early tumor stages.
Alternatively, host immune response against cancer cells
may decrease with increasing tumor growth [4].
Several groups found stage specific beneficial effects of
infiltrating lymphocytes on clinical outcome [30-33].
Guidoboni et al. described a correlation between the
presence of cytotoxic T lymphocytes and improved sur-
vival in stage II and III colorectal tumors irrespective of
the MSI-status [30]. These results were confirmed by
Figure 2 Semiquantitative scoring of inflammatory infiltration. Semiquantitative scoring of inflammatory infiltration of the three different tumor 
regions, based on two levels of infiltration (null-mild versus moderate-severe). (IM: invasive margin, ST: stroma, CC: cancer cell nests, GRB: granzyme B, 
CD8*GRB: CD8 T cells expressing GRB).Deschoolmeester et al. BMC Immunology 2010, 11:19
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Prall et al. [31] for stage III disease. However, when MSI-
status was taken into account, the correlation with sur-
vival was most pronounced when both MSI-H and intra-
tumoral-activated cytotoxic T lymphocytes were present
in stage III tumors [30].
In this study, stage specific survival analysis did not
show a major influence of tumor infiltration on overall
survival. However, given the relative small number of
cases per stage group, such an influence might be difficult
to detect. Nevertheless, this could be of interest since we
previously showed a significant beneficial effect of active
specific immunotherapy in adjuvant treatment of patients
with stage II colon cancer only [32].
Accumulating evidence indicates that most MSI-posi-
tive colorectal tumors are characterized by the presence
of a pronounced intratumoral inflammatory reaction, the
nature of which, however, is still poorly understood
[30,51]. Within these tumors, tumor infiltrating lympho-
cytes have been identified as predominantly activated
CD8+ T cells. The presence of these cytotoxic T lympho-
cytes has been attributed to the inherently greater pro-
duction of abnormal peptides as a result of unreliable
DNA repair in MSI-positive tumors [37]. In the current
study, among the different clinicopathological parameters
analyzed, MSI was strongly correlated with a high pres-
ence of activated cytotoxic intraepithelial lymphocytes.
Nevertheless, survival analysis by MSI-status revealed
that, despite the high infiltration of lymphocytes in MSI-
positive colorectal tumors, no association was found with
a favorable prognosis within this subset. These data are in
agreement with some studies [31,37,50,52-57], but they
are in conflict with a number of other reports [13,24-
Figure 3 Kaplan-Meier survival curves for infiltrating lymphocytes in colorectal cancer. Kaplan-Meier curves for overall survival among colorec-
tal cancer patients according to (A) the infiltration of CD3+ lymphocytes in the cancer cell nests and (B) the stroma, (C) according to the infiltration of 
CD8+ lymphocytes in the cancer cell nests and (D) according to the infiltration of CD8+ lymphocytes in the cancer cell nests of MSS tumors (IM: invasive 
margin, ST: stroma, CC: cancer cell nests, MSS: microsatellite stable).Deschoolmeester et al. BMC Immunology 2010, 11:19
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27,30,34,58] in which a predominant presence of intra-
tumor cell infiltrating lymphocytes in MSI-H cancers was
significantly correlated with a better prognosis. In accor-
dance to Baker et al. [37], MSS colorectal tumors with
infiltration of CD8+  tumor infiltrating lymphocytes
showed a better overall survival. One explanation might
be that the functions of tumor infiltrating lymphocytes
d i f f e r  b e t w e e n  t h e s e  s u b g r o u p s .  I t  i s  p o s s i b l e  t h a t  t h e
high prevalence of recruitment and retention of tumor
infiltrating lymphocytes in MSI-positive colorectal
tumors is inherent to the unique aspect of the tumor biol-
ogy, supporting the hypothesis that the genetic instability
of MSI-positive colorectal tumors may lead to the pro-
duction of a greater number of tumor specific antigens
that trigger the immune system [7,11-16,27,30]. As
described previously [59], direct contact between tumor
cells, presenting these aberrant peptides, and leucocytes
plays a crucial role in the immune reaction. However, the
concept of cross-priming in which antigen presenting
cells pick up antigens released by dead tumor cells and
subsequently present them to T cells may also be impor-
tant in vivo [42].
On the other hand, MSI-positive tumors can undergo
immuno-editing, which dictates that tumors reaching the
stage of clinical detection have been shaped antigenically
by the initial immune responses mounted against them to
a point where they are no longer recognized as foreign to
the body. In MSS tumors, which arise in a much less
immunologically stimulating environment, the tumors
are less likely to have adapted antigenically and may thus
be more sensitive to late stage immune attack. Thus, even
though MSI-positive tumors produce more tumor spe-
cific antigens that might trigger the immune system, the
elevated levels of these antigens in combination with the
lack of appropriate costimulatory molecules on the tumor
cells may generate a microenvironment which leads to a
state of tumor infiltrating lymphocyte anergy, thereby
preempting any beneficial effect on survival [12,37]. In
addition, the expression of HLA class I proteins, present-
ing tumor associated antigens on the tumor cell surface,
is considered a prerequisite for an effective T cell immune
response [60]. It has been described that genetically
unstable tumors are often HLA class I negative and might
escape T-cell mediated immune killing. However, in the
absence of any surface HLA class I these tumors would be
susceptible to a natural killer cell attack. In contrast,
those tumors that downregulate specific HLA class I
alleles may avoid both T cell and natural killer cell activa-
Table 3: Survival analysis using a Cox regression model.
Overall survival Disease free survival
Cox Regression Cox Regression
HR 95%CI p-value HR 95%CI p-value
MSI 0.38 0.12 1.18 0.09 0.33 0.09 1.27 0.11
Age 1.04 1.00 1.07 0.04 0.97 0.92 1.01 0.14
Gender 1.41 0.79 2.53 0.25 1.45 0.68 3.13 0.34
Localization 0.71 0.38 1.31 0.27 1.16 0.47 2.84 0.75
Grade of 
differentiation
0.70 0.43 1.13 0.15 0.53 0.34 1.09 0.05
stage 2.37 1.58 3.56 < 0.001 2.70 1.51 4.83 < 0.001
adjuvant 
treatment
0.70 0.29 1.68 0.43 1.03 0.36 2.97 0.96
CD8IM 1.24 0.56 2.75 0.59 0.82 0.29 2.36 0.71
CD8ST 0.89 0.38 2.10 0.79 1.95 0.66 5.76 0.22
CD8CC 2.06 0.67 6.39 0.21 0.68 0.16 2.88 0.60
CD3IM 0.97 0.40 2.32 0.94 0.86 0.27 2.75 0.80
CD3ST 1.05 0.51 2.19 0.89 0.66 0.24 1.85 0.43
CD3CC 0.54 0.18 1.59 0.26 1.61 0.44 5.95 0.48
GRBIM 0.59 0.24 1.44 0.24 1.14 0.37 3.52 0.81
GRBST 0.86 0.37 2.00 0.72 0.53 0.17 1.65 0.27
GRBCC 1.18 0.45 3.13 0.74 2.18 0.62 7.61 0.22
Survival analysis of colorectal cancer patients using a multiple Cox regression model. (HR: hazard ratio, CI: confidence interval, IM: invasive 
margin, ST: stroma, CC: cancer cell nests, GRB: granzyme B, MSI: microsatellite instability).Deschoolmeester et al. BMC Immunology 2010, 11:19
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tion [20]. Therefore, Speetjens et al. [60] hypothesized
that both oncogenic pathway and HLA class I expression
might dictate clinical tumor progression. Furthermore,
insufficient evidence exists to recommend routine use of
biological factors as MSI for either determining prognosis
or predicting response to therapy in colorectal cancer
patients [61].
When entered into a multiple Cox regression analysis
adjusting for other possible important confounding fac-
tors, only early stage and young age (borderline signifi-
cant for overall population only) were associated with a
better overall survival (early stage also with disease-free
survival). The beneficial effect of tumor infiltrating lym-
phocytes in colorectal cancer could not be confirmed in
the Cox regression survival analysis.
In summary, this study confirms that tumor infiltrating
lymphocytes are indeed important clinical and prognos-
tic indicators in colorectal cancer, in univariate analysis,
irrespective of the MSI-status. Therefore, it was consid-
ered that tumor infiltration could reflect a general princi-
ple of antitumor immunity as mentioned by Prall et al.
[31]. In addition, in accordance with Baker et al., we also
demonstrated an important disease-specific survival
advantage for patients with MSS tumors containing intra-
epithelial CD8+  tumor infiltrating lymphocytes [37].
Although no stage specific survival difference of tumor
infiltrating lymphocytes was noted in colorectal cancer, it
was demonstrated that stage was also a major determi-
nant of the presence of tumor infiltrating lymphocytes in
Figure 4 Kaplan-Meier survival curves for infiltrating lymphocytes in colon cancer only. Kaplan-Meier curves for overall survival among colon 
cancer patients according to (A) the infiltration of CD3+ lymphocytes in the cancer cell nests and (B) the stroma, (C) according to the infiltration of 
CD8+ lymphocytes in the cancer cell nests and (D) according to the infiltration of CD8+ lymphocytes in the cancer cell nests of MSS tumors (IM: invasive 
margin, ST: stroma, CC: cancer cell nests, MSS: microsatellite stable).Deschoolmeester et al. BMC Immunology 2010, 11:19
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colorectal cancer, with a higher infiltration in earlier
stages.
We would like to note that the tumor immune response
does not only depend on infiltration and activation of T
lymphocytes. Therefore, the minute balanced association
of all infiltrating cells, their capability to synthesize and
release tumor-modifying substances, and their content of
presynthesized, granule-associated bioactive substances
deserves intensive study. By doing so, new biological
tumor-host responses may be disclosed, leading to the
development of new approaches to the treatment of
malignant disease [45].
Methods
Tissue samples
Tumor DNA was obtained from 215 patients with surgi-
cally resected colorectal cancer, treated between 1995
and 2003, from the Antwerp University Hospital and the
St. Augustinus Hospital Antwerp. The study was
approved by the local Ethics Committee of the University
of Antwerp and was conducted in accordance with the
ethical principles stated in the most recent version of the
Declaration of Helsinki.
Immunohistochemistry
Five μm-thick sections were prepared from formalin-
fixed paraffin-embedded tissue for IHC. Sections were
deparaffinized in toluene, dehydrated and subjected to
heat antigen retrieval by T ris EDT A buffer (pH 9) in a
heating bath for 30 min. at 95 (± 1)°C.
Sections were subsequently stained using the Dako
Autostainer Plus system (DAKO, DakoCytomation,
Glostrup, Denmark). Endogenous peroxidase activity was
quenched by incubating the slides in peroxidase block
EnVision Plus (DAKO EnVision™ kit, DakoCytomation,
Glostrup, Denmark) for 10 minutes. Incubation with pri-
mary monoclonal antibodies against: CD3 (clone SPF7,
diluted 1:150, Neo-Markers, CA, USA), CD8 (clone 1A5,
diluted 1:20, Novacastra Laboratories Ltd, Newcastle
upon Tyne, UK) and Granzyme B (clone GRB7, diluted
1:25, DAKO, DakoCytomation, Glostrup, Denmark) was
performed for 30 minutes at room temperature. Sites of
binding were detected using the Envision dual link detec-
tion system (DAKO EnVision™ kit, DakoCytomation,
Glostrup, Denmark) with 3,3'-diaminobenzidine (DAB+)
as chromogen according to the manufacturer's instruc-
tions. The sections were counterstained with haematoxy-
lin, dehydrated, cleared and mounted.
Classification and quantification of lymphocytes
Inflammatory infiltration by CD3+ (early T cell marker),
CD8+(cytotoxic T cell marker) T lymphocytes and the
expression of Granzyme B (marker for cytotoxic cells
after cell activation) were immunohistochemically scored
in three regions of the tumor as described by Naito et al.
[24]: a) those distributed along the invasive margin of the
tumor, b) those infiltrated in cancer stroma and c) those
infiltrated in the tumor cell nests.
Each entire tumor section was evaluated for infiltrating
cells by using a × 10 objective lens. The number of lym-
phocytes infiltrating the tumor cell nests was counted in
five visual fields, selected for most abundant distribution
under a light microscope at × 400 magnification, corre-
sponding to a total area of 1.19 mm2. The degree of infil-
tration was classified as follows: nil: 0, mild: 1-19,
moderate: 20-49 and severe: ≥ 50 positive cells [24].
For all other regions of the tumor, immune reactivity
was scored semi-quantitatively (nil, mild, moderate and
severe) as described by Naito et al., [24] Scoring was per-
formed by two independent observers, if no consensus
could be reached a third observer was consulted.
MSI analysis
All cases had been previously analyzed for MSI-status
[62]. After manual microdissection of formalin-fixed,
paraffin embedded tissue blocks, DNA was isolated as
described previously [63]. MSI analysis was performed
using the mononucleotide multiplex system as described
earlier [35]. In short, the sense primers were chemically
labeled at the 5' end with FAM™ fluorescent dyes. PCR
was carried out in a final volume of 25 μl containing 200
μmol/L dNTPs (MBI Fermentas, St. Leon-Rot, Ger-
many), 500 nM of each sense and antisense primer (Euro-
gentec, Seraing, Belgium), 1 × PCR buffer (60 mM Tris
SO4 (pH 8.9), 18 mM (NH4)SO4 and 2 mM MgSO4) and 1
unit Discoverase dHPLC DNA polymerase (Invitrogen,
Merelbeke, Belgium). Fluorescent PCR products were
analyzed by capillary electrophoresis using an ABI 3100
Genetic Analyzer (Applied Biosystems, Lennik, Belgium)
and Genemapper Software 3.7.
Statistical analysis
Prognostic relevance of lymphocyte infiltration was
assessed by survival analysis.
The index date for survival time calculation was
defined as the date of surgery for colorectal cancer. The
months of observation (= overall survival time) were cal-
culated from the index date to the date of last informa-
tion/death. For disease free survival time the months of
observation were calculated from the index date to the
first date of progressive disease. Survival curves were
determined by using the Kaplan-Meier method and were
analyzed by using the log-rank test.
Possible associations between MSI-status and the
immunophenotypic markers and clinicopathological
parameters of colorectal cancers were investigated using
the χ2-test or Fisher's exact test (when numbers expected
per cell are less than 5) for categorical variables and usingDeschoolmeester et al. BMC Immunology 2010, 11:19
http://www.biomedcentral.com/1471-2172/11/19
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Student t-test (for unpaired comparisons based on
numerical variables for which the assumption of a normal
distribution was appropriate (i.e. Kolmogorov-Smirnoff
test p > 0.02)) or its nonparametric alternative Mann-
Whitney U test (for unpaired comparisons based on
numerical variables for which the assumption of a normal
distribution was not appropriate) for continuous vari-
ables. In order to assess the independent prognostic con-
tribution of the cytotoxic T lymphocytes, a multiple Cox
regression analysis was conducted. All analyses were con-
ducted using SPSS (version 16.0). Significance for all sta-
tistics was recorded if p < 0.05 (two-tailed).
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